BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010; 16(38): 4784-4791 [PMID: 20939106 DOI: 10.3748/wjg.v16.i38.4784] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Lv WS, Sun RX, Gao YY, Wen JP, Pan RF, Li L, Wang J, Xian YX, Cao CX, Zheng M. Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes. World J Gastroenterol 2013; 19(20): 3134-3142 [PMID: 23716995 DOI: 10.3748/wjg.v19.i20.3134] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
2 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
3 Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol 2015; 7(25): 2597-2602 [PMID: 26557952 DOI: 10.4254/wjh.v7.i25.2597] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
4 Davarpanah AH, Weinreb JC. The role of imaging in hepatocellular carcinoma: the present and future. J Clin Gastroenterol. 2013;47 Suppl:S7-10. [PMID: 23632342 DOI: 10.1097/mcg.0b013e31827f0d3d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
5 Ricchi P, Meloni A, Costantini S, Spasiano A, Di Matola T, Pepe A, Cinque P, Filosa A. Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia. Ann Hematol 2017;96:1541-6. [PMID: 28707012 DOI: 10.1007/s00277-017-3057-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Massart J, Begriche K, Moreau C, Fromenty B. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res 2017;3:212-32. [PMID: 28691103 DOI: 10.18053/jctres.03.2017S1.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
7 Jeon D, Son M, Shim J. Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status. Nutrients 2021;13:1720. [PMID: 34069568 DOI: 10.3390/nu13051720] [Reference Citation Analysis]
8 Schild BZ, Santos LN, Alves MK. [Nonalcoholic fatty liver disease and its association with metabolic syndrome in the preoperative period in patients undergoing bariatric surgery]. Rev Assoc Med Bras (1992) 2013;59:155-60. [PMID: 23582557 DOI: 10.1016/j.ramb.2012.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
9 Siegert S, Yu Z, Wang-Sattler R, Illig T, Adamski J, Hampe J, Nikolaus S, Schreiber S, Krawczak M, Nothnagel M. Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. PLoS One. 2013;8:e76813. [PMID: 24130792 DOI: 10.1371/journal.pone.0076813] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
10 Mora SI, García-román J, Gómez-ñañez I, García-román R. Chronic liver diseases and the potential use of S-adenosyl-l-methionine as a hepatoprotector. European Journal of Gastroenterology & Hepatology 2018;30:893-900. [DOI: 10.1097/meg.0000000000001141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Salman AA, Aboelfadl SA, Heagzy MA. New Era for Usage of Serum Liver Enzymes as A Promising Horizon for the Prediction of Non-Alcoholic Fatty Liver Disease. Open Access Maced J Med Sci 2016;4:348-52. [PMID: 27703554 DOI: 10.3889/oamjms.2016.092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti S, Ricchiuti A, De Bortoli N, Marchi S, Pompella A. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int. 2012;32:629-634. [PMID: 22098947 DOI: 10.1111/j.1478-3231.2011.02673.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
13 Käkelä P, Rantanen T, Paajanen H, Virtanen KA. Fatal complications after an interrupted gastric bypass operation in a patient with non-alcoholic fatty liver disease and massive obesity: a case report. J Surg Case Rep 2021;2021:rjab247. [PMID: 34178303 DOI: 10.1093/jscr/rjab247] [Reference Citation Analysis]
14 Yen Y, Kuo F, Lin C, Chen C, Chang K, Tsai M, Hu T. Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter. Transplantation Proceedings 2018;50:3533-8. [DOI: 10.1016/j.transproceed.2018.06.039] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
15 Surapaneni KM, Jainu M. Pioglitazone, quercetin and hydroxy citric acid effect on hepatic biomarkers in Non Alcoholic Steatohepatitis. Pharmacognosy Res 2014;6:153-62. [PMID: 24761121 DOI: 10.4103/0974-8490.129037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
16 Shih KL, Su WW, Chang CC, Kor CT, Chou CT, Chen TY, Wu HM. Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:24031. [PMID: 27079922 DOI: 10.1038/srep24031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
17 Massart J, Begriche K, Corlu A, Fromenty B. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease. IJMS 2022;23:1062. [DOI: 10.3390/ijms23031062] [Reference Citation Analysis]
18 Hegazy M, Abo-Elfadl S, Mostafa A, Ibrahim M, Rashed L, Salman A. Serum Resistin Level and Its Receptor Gene Expression in Liver Biopsy as Predictors for the Severity of Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol 2014;4:59-62. [PMID: 29699348 DOI: 10.5005/jp-journals-10018-1102i] [Reference Citation Analysis]
19 Almobarak AO, Barakat S, Suliman EA, Elmadhoun WM, Mohamed NA, Abobaker IO, Noor SK, Bushara SO, Ahmed MH. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit? Arab J Gastroenterol 2015;16:54-8. [PMID: 26174761 DOI: 10.1016/j.ajg.2015.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
20 Gao X, Shi D, Chen Y, Cui J, Wang Y, Jiang C, Wu J. The therapeutic effects of tectorigenin on chemically induced liver fibrosis in rats and an associated metabonomic investigation. Arch Pharm Res 2012;35:1479-93. [DOI: 10.1007/s12272-012-0819-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
21 AlShaalan R, Aljiffry M, Al-Busafi S, Metrakos P, Hassanain M. Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis. Saudi J Gastroenterol. 2015;21:64-70. [PMID: 25843191 DOI: 10.4103/1319-3767.153812] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Razavizade M, Jamali R, Arj A, Talari H. Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2012;11:513-520. [PMID: 23060397 DOI: 10.1016/s1499-3872(12)60216-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
23 Asimakopoulou A, Weiskirchen R. Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis. Clinical Lipidology 2015;10:47-67. [DOI: 10.2217/clp.14.65] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Bouzianas DG, Bouziana SD, Hatzitolios AI. Potential treatment of human nonalcoholic fatty liver disease with long-chain omega-3 polyunsaturated fatty acids. Nutr Rev. 2013;71:753-771. [PMID: 24148001 DOI: 10.1111/nure.12073] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
25 Terán Lantarón A, Crespo García J. [Non-alcoholic fatty liver disease. How and who to screen]. Gastroenterol Hepatol 2011;34:278-88. [PMID: 21429628 DOI: 10.1016/j.gastrohep.2010.11.010] [Reference Citation Analysis]
26 Asimakopoulou A, Weiskirchen S, Weiskirchen R. Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy. Front Physiol 2016;7:430. [PMID: 27729871 DOI: 10.3389/fphys.2016.00430] [Cited by in Crossref: 44] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
27 Kim E, Kang Y, Hahn S, Lee MJ, Park YN, Koh H. The efficacy of aspartate aminotransferase-to-platelet ratio index for assessing hepatic fibrosis in childhood nonalcoholic steatohepatitis for medical practice. Korean J Pediatr 2013;56:19-25. [PMID: 23390441 DOI: 10.3345/kjp.2013.56.1.19] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
28 Miles DA, Levi CS, Uhanova J, Cuvelier S, Hawkins K, Minuk GY. Pocket-Sized Versus Conventional Ultrasound for Detecting Fatty Infiltration of the Liver. Dig Dis Sci 2020;65:82-5. [DOI: 10.1007/s10620-019-05752-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
29 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther. 2011;9:321-328. [PMID: 21438811 DOI: 10.1586/erc.11.15] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
30 Fisher CP, Kierzek AM, Plant NJ, Moore JB. Systems biology approaches for studying the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(41): 15070-15078 [PMID: 25386055 DOI: 10.3748/wjg.v20.i41.15070] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
31 Eslamparast T, Eghtesad S, Poustchi H, Hekmatdoost A. Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol 2015; 7(2): 204-212 [PMID: 25729475 DOI: 10.4254/wjh.v7.i2.204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 6.1] [Reference Citation Analysis]
32 Li SM, Li GX, Fu DM, Wang Y, Dang LQ. Liver fibrosis evaluation by ARFI and APRI in chronic hepatitis C. World J Gastroenterol 2014; 20(28): 9528-9533 [PMID: 25071348 DOI: 10.3748/wjg.v20.i28.9528] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
33 Milovanovic Alempijevic T, Stojkovic Lalosevic M, Dumic I, Jocic N, Pavlovic Markovic A, Dragasevic S, Jovicic I, Lukic S, Popovic D, Milosavljevic T. Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assessment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients. Can J Gastroenterol Hepatol 2017;2017:6070135. [PMID: 29464178 DOI: 10.1155/2017/6070135] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
34 Zhong LK, Zhang G, Luo SY, Yin W, Song HY. The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B. J Clin Lab Anal 2020;34:e23270. [PMID: 32363594 DOI: 10.1002/jcla.23270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol. 2013;58:1007-1019. [PMID: 23183525 DOI: 10.1016/j.jhep.2012.11.021] [Cited by in Crossref: 237] [Cited by in F6Publishing: 203] [Article Influence: 23.7] [Reference Citation Analysis]
36 Caballería L, Saló J, Berzigotti A, Planas R, Vila C, Huertas C, Torres M, Torán P, Caballería J. Hígado graso no alcohólico. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2014;37:372-83. [DOI: 10.1016/j.gastrohep.2014.03.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 13.6] [Reference Citation Analysis]
38 Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5(3): 109-113 [PMID: 23556042 DOI: 10.4254/wjh.v5.i3.109] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
39 Le Corvec M, Allain C, Lardjane S, Cavey T, Turlin B, Fautrel A, Begriche K, Monbet V, Fromenty B, Leroyer P, Guggenbuhl P, Ropert M, Sire O, Loréal O. Mid-infrared fibre evanescent wave spectroscopy of serum allows fingerprinting of the hepatic metabolic status in mice. Analyst 2016;141:6259-69. [DOI: 10.1039/c6an00136j] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
40 Lim U, Turner SD, Franke AA, Cooney RV, Wilkens LR, Ernst T, Albright CL, Novotny R, Chang L, Kolonel LN, Murphy SP, Le Marchand L. Predicting total, abdominal, visceral and hepatic adiposity with circulating biomarkers in Caucasian and Japanese American women. PLoS One 2012;7:e43502. [PMID: 22912885 DOI: 10.1371/journal.pone.0043502] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 3.4] [Reference Citation Analysis]
41 Kapoor N, Audsley J, Rupali P, Sasadeusz J, Paul TV, Thomas N, Lewin SR. A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries. AIDS 2019;33:1105-15. [PMID: 31045941 DOI: 10.1097/QAD.0000000000002161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]